GB2280370A - Pharmaceutical composition for the treatment of chronic skin ulcers - Google Patents
Pharmaceutical composition for the treatment of chronic skin ulcers Download PDFInfo
- Publication number
- GB2280370A GB2280370A GB9413939A GB9413939A GB2280370A GB 2280370 A GB2280370 A GB 2280370A GB 9413939 A GB9413939 A GB 9413939A GB 9413939 A GB9413939 A GB 9413939A GB 2280370 A GB2280370 A GB 2280370A
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical composition
- boric acid
- skin ulcers
- chronic skin
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
2280370 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CHRONIC SKIN
ULCERS The present invention relates to improvements in More particularly, the invention is directed to a pharmaceutical composition for topical use in the treatment of chronic skin ulcers.
Persons suffering from diabetes are prone to ulceration of their extremities such as hands and feet, due to the high sugar content of the blood which impairs blood circulation. Skin ulcers are characterized by a loss of epidermis and at least part of the dermis, which generally leads to chronic bacterial infections. These infections seldom respond to systemic antibiotics since the poor circulatory system of a diabetic prevents an adequate supply of blood to the extremities, and thus of the antibiotics. Topical antibiotics, on the other hand, are ineffective in most bacterial skin infections Pnd may cause allergic contact dermatitis. As a result, the infection cannot be controlled and in order to prevent it from spreading to adjacent parts of the body, the diabetic has no other alternative but to undergo amputation of the infected extremity.
It is therefore an object of the present invention to overcome the above drawbacks and to provide a pharmaceutical composition for the treatment of chronic skin ulcers.
In accordance with the present invention, there is thus provided a pharmaceutical composition for treating chronic skin ulcers and comprising, as active ingredient, a mixture of 4-chloro-3,5dimethylphenol and boric acid, together with a therefor.
the field of topical dermatologic therapy.
pharmaceutically acceptable carrier - 2 Applicant has found quite unexpectedly that 4chloro-3,5-dimethylphenol when used in admixture with boric acid is highly effective for treating chronic skin ulcers. The composition of the invention not only enables the infection to be cleared up, but also promotes skin granulation without the formation of scars.
In a preferred embodiment of the invention, the composition comprises about 1 wt.% of 4-chloro-3,5dimethylphenol and about 6 wt.% of boric acid, based on the total weight of the composition. Preferably, the pharmaceutically acceptable carrier is water.
4-Chloro-3,5-dimethylphenol is preferably used in the form of a solution which is sold under the trademark DETTOL and contains about 5 wt.% of 4chloro3,5-dimethylphenol, about 8 wt.% of pine oil and about 9 wt.% of isopropyl alcohol, the remainder being water. Approximately 40 parts by volume of such a solution are admixed with about 7 parts by volume of boric acid, and the resulting solution is diluted with approximately 123 parts by volume of water. A preferred composition according to the invention thus comprises about 1 wt.% of 4-chloro-3,5-dimethylphenol, about 6 wt.% of boric acid, about 2 wt.% of pine oil and about 2 wt.;- of isopropyl alcohol, the remainder being water.
The pharmaceutical composition of the invention is applied to the wound area of the skin and maintained in contact therewith for a period of approximately 20 minutes, for example, by immersing the infected extremity in a bath containing the treating solution in the case where the skin ulcer is located on one's hand or foot. After immersion, the wound area with the treating solution 3 thereon is covered with a gauze bandage. Such a treatment is repeated every 12 hours until complete healing of the wound is achieved.
It is believed that 4-chloro-3,5-dimethylphenol and boric acid coact synergistically to suppress bacterial activity and stimulate cell growth. The healing process proceeds without the formation of scars.
The following non-limiting example illustrates the invention.
EXAMPLE
A pharmaceutical composition for treating skin ulcers was prepared by mixing the following ingredients:
- DETTOL: 400 ml - Boric acid 70 ml - Water: 1230 ml The resulting solution was applied to a chronic skin ulcer on a diabetic's foot by immersing the foot in a bath containing the solution, for a period approximately 20 minutes. After immersion, the wound area 20 with the treating solution thereon was covered with a of gauze bandage. This treatment was repeated every 12 hours. Complete healing of the ulcer was observed after approximately six months of treatment.
4 -
Claims (12)
1. A pharmaceutical composition for thetreatment of chronic skin ulcers, comprising as active ingredient a mixture of 4-chloro-3,5-dimethylphenol and boric acid, together with a pharmaceutically acceptable carrier therefor.
2. A pharmaceutical composition according to claim 1, comprising about 1 wt.% of 4-chloro-3,5-dimethylphenol and about 6 wt.% of boric acid, based on the total weight of the composition.
3. A pharmaceutical composition according to claim 1 or 2, wherein the pharmaceutically acceptable carrier is water.
4. A pharmaceutical composition according to claim 1 or 2, further comprising about 8 wt.% of pine oil and about 9 wt.% of isopropyl alcohol, based on the total weight of the composition.
5. A pharmaceutical composition according to claim 1, comprising about 40 parts by volume of DETTOL (trademark), about 7 parts by volume of boric acid and about 123 parts by volume of water.
6. Use of 4-chlorc-3,5-dimethylphenol in admixture with boric acid for treating chronic skin ulcers.
7. Use of DETTOL (trademark) in admixture with boric acid for treating chronic skin ulcers.
8. A pharmaceutical composition according to claim 1, substantially as described herein.
9. 4-Chloro-3,5-dirnethylphenol together with boric acid for use as a pharmaceutical composition for topical administration.
10. 4-Chloro-3,5-dimethylphenol together with boric acid for the treatment of chronic skin ulcers.
11. Use of 4-chloro-3,5-dimethylphenol together with boric acid for the manufacture of a pharmaceutical composition for the treatment of chronic skin ulcers.
12. A combined preparation or pack for the treatment of chronic skin ulcers, which comprises (a) 4-chloro-3,5-dimethylphenol, and (b) boric acid, the components being present together in the same formulation or in separate formulations for simultaneous or sequential administration, and, where appropriate or desired, instructions for use of the components together or sequentially.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2100314 CA2100314C (en) | 1993-07-12 | 1993-07-12 | Pharmaceutical composition for the treatment of chronic skin ulcers |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9413939D0 GB9413939D0 (en) | 1994-08-31 |
GB2280370A true GB2280370A (en) | 1995-02-01 |
Family
ID=4151918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9413939A Withdrawn GB2280370A (en) | 1993-07-12 | 1994-07-11 | Pharmaceutical composition for the treatment of chronic skin ulcers |
Country Status (4)
Country | Link |
---|---|
CA (1) | CA2100314C (en) |
DE (1) | DE4424548A1 (en) |
FR (1) | FR2707497A1 (en) |
GB (1) | GB2280370A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100222301A1 (en) * | 2010-02-06 | 2010-09-02 | Javid Mihan Jafari | Topical drug for treatment and/or prevention of diabetic neuropathy, microangiopathy and diabetic and non diabetic ulcers and wound infection |
-
1993
- 1993-07-12 CA CA 2100314 patent/CA2100314C/en not_active Expired - Fee Related
-
1994
- 1994-07-11 FR FR9408541A patent/FR2707497A1/en not_active Withdrawn
- 1994-07-11 GB GB9413939A patent/GB2280370A/en not_active Withdrawn
- 1994-07-12 DE DE19944424548 patent/DE4424548A1/en not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100222301A1 (en) * | 2010-02-06 | 2010-09-02 | Javid Mihan Jafari | Topical drug for treatment and/or prevention of diabetic neuropathy, microangiopathy and diabetic and non diabetic ulcers and wound infection |
EP2353585A3 (en) * | 2010-02-06 | 2012-02-22 | Dr. Mihan Jafari Javid | Topical drug for treatment and/or prevention of diabetic neuropathy, microangiopathy and diabetic and non diabetic ulcers and wound infection |
Also Published As
Publication number | Publication date |
---|---|
FR2707497A1 (en) | 1995-01-20 |
CA2100314C (en) | 1996-04-16 |
GB9413939D0 (en) | 1994-08-31 |
CA2100314A1 (en) | 1995-01-13 |
DE4424548A1 (en) | 1995-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0112852B1 (en) | Pharmaceutical gel composition | |
US4725609A (en) | Method of promoting healing | |
EP0789584B1 (en) | Application of superoxide dismutase in liposomes | |
US4401651A (en) | Wound-healing compositions containing povidone-iodine | |
CN105142728B (en) | Compositions and methods for treating surface wounds | |
US4424232A (en) | Treatment of herpes simplex | |
US20050181028A1 (en) | Topical composition and method for treating occlusive wounds | |
JP2005505543A (en) | Emu base preparation for wound treatment | |
US4735802A (en) | Topical dermatological composition and method of treatment | |
Margraf et al. | A trial of silver-zinc-allantoinate in the treatment of leg ulcers | |
US5116617A (en) | Pharmaceutical composition for topical use in the treatment of the capillary fragility | |
US6465514B1 (en) | Methods and compositions for the promotion of hair growth | |
RU2202362C2 (en) | Composition for topical usage containing human epidermis factor growth | |
US6503946B1 (en) | Preparation for warts | |
CA2100314C (en) | Pharmaceutical composition for the treatment of chronic skin ulcers | |
KR960005144B1 (en) | Topical composition for acceleration wound healing | |
EP0699443B1 (en) | Elder-containing skin preparation | |
US5616619A (en) | Topical composition for burn relief and method of use | |
RU2177314C2 (en) | Composition eliciting antiseptic, reparative and analgetic properties | |
WO2005077402A1 (en) | Honey based gel formulations | |
RU2781402C2 (en) | Niosomal antimicrobial gel for treating diabetic ulcers, wounds, burns, including those infected with antibiotic-resistant microorganisms | |
US5576005A (en) | Effectiveness of wart removal by compositions including propolis | |
AU687840B2 (en) | Topical composition for burn relief and method of use | |
AU558482B2 (en) | Pharmaceutical gel composition | |
US6395779B1 (en) | Method of treatment using peroxidized lipids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |